Skip to main content

Table 2 Impact of clofarabine on patients with a high MRD (N=8)

From: French “real life” experience of clofarabine in children with refractory or relapsed acute lymphoblastic leukaemia

MRD evolution Number (%)
Improvement of one logarithm 1 (12.5%)
Improvement of less than one logarithm 3 (37.5%)
Stable 3 (37.5%)
Non evaluable 1 (12.5%)